AKT1 and cancer: ,2 Cancer therapy often causes cutaneous adverse reactions, but there is a lack of scientific literature describing clinical and histopathological characteristics of skin eruptions associated with AKT inhibitors despite the high prevalence of cutaneous reactions experienced by patients on capivasertib therapy in clinical trials.